long intergenic non-protein coding RNA 1519Genealiases: []
Q-omics provides the consensus-scored LINC01519 profile across patient tissues and cancer cell-line models. LINC01519 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LINC01519 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, LINC01519 RNA expression shows 6,139 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, THCA, and STAD as cancer lineages where LINC01519 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01519 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01519 survival associations across molecular data types. LINC01519 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01519 RNA expression–survival associations across cancer types. High LINC01519 expression shows unfavorable associations in MESO, KIRP, PAAD, LGG, UCEC and LUAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for LINC01519 RNA expression.
This table summarizes LINC01519 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01519. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01519 shows lower tumor expression in THCA and KIRC. The THCA box plot shows higher LINC01519 RNA expression in normal versus tumor tissue (log2 FC = −0.274, t-test p < 0.001).
This table shows molecular features associated with LINC01519 in patient tissues and cancer cell lines. In patient samples, LINC01519 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
